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ABSTRACT
Cell-based immunotherapies are a new generation of “living-drug” treatments for cancer
and other diseases. Chimeric antigen receptor (CAR) T-cell cancer therapy has shown promising
results in lymphoma and B-cell malignancies. Currently, there are six FDA-approved CAR-T
drugs on the market, and all of them use viral transfection for reprogramming. While viral
transfection is effective, there are safety concerns due to inconsistent transfection that limit the use
of CAR-T therapy. Current non-viral transfection techniques generally have lower transfection
efficiency than viral transfection. Additionally, these techniques can be toxic, time-consuming,
non-transportable, and expensive. To address these limitations, a novel 3D printed acoustofluidic
system is being explored for inducing intracellular molecular delivery of therapeutic compounds
for genetic editing. This system utilizes sonoporation, which creates reversible pores in the cell
membrane when ultrasound waves rupture microbubbles. A solution of cells, microbubbles, and
molecules of interest pass through fluidic channels and microbubbles rupture once exposed to
ultrasound waves. A shockwave is created, which propels nearby material into the cell within
seconds. In this thesis, several studies were conducted to assess the acoustofluidic mediated
intracellular molecular delivery of compounds such as 150kDa FITC-Dextran, fluorescently
labeled tracrRNA, and green fluorescent protein (GFP) in multiple cell lines. These studies indicate
that cationic microbubbles alongside acoustofluidic treatment significantly increase intracellular
molecular delivery of several different compounds. These studies show promise for the use of 3D
printed acoustofluidic device for non-viral transfection of CRISPR/Cas9 in CAR-T cell
processing.
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I.

INTRODUCTION
Objective
This thesis aims to assess the efficiency of a 3D-printed acoustofluidic device for
the molecular delivery of various fluorescent compounds into four cell types. The longterm goal is to develop new acoustofluidic techniques to improve cell processing methods
for immunotherapies.
Overview of CAR-T and Molecular Delivery
Cell-based immunotherapies are a growing field for the treatment of cancers and
other diseases. Chimeric Antigen Receptor-T cell (CAR-T) therapy utilizes gene
transfections techniques to re-program T-cells with desired surface markers and antigens
(Figure 1). CAR-T cells are activated once they recognize the target antigen or surface
marker on cancer cells and release chemokines and inflammatory cytokines to eliminate
the cancer cell. A blood sample is received from the patient, and T-cells are isolated from
the blood sample to reengineer

those

T-cells

with a specific CAR gene
to express the desired
function. Then the reengineered

cells

are

proliferated ex vivo before
patient

Figure 1: CAR-T cell processing steps are shown in this graphical

re-infusion. representation from leukapheresis, T-cell transfection, T-cell expansion
ex-vivo, and reinfusion of CAR-T cells in the patient [1].
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Current cancer treatments include surgery, chemotherapy, and radiation. CAR-T therapy
is an alternative treatment option for patients who may not respond well to current
treatment plans. CAR-T is an exciting option for patients because it is a “living drug”
targeted for patient-specific cancer. The essential components of CAR-T include an
extracellular antigen recognition domain, a transmembrane domain, and an intracellular
signaling domain [2]. CAR-T therapy was first approved for cancer treatment in 2017.
Currently, there are six FDA-approved CAR-T products: Yescarta (Axi-cel), Kymriah
(Tisa-cel),

Breyanzi(Liso-cel),

and

Tecartus(Brexu-cel),

Abecma

(ide-cel)

and

Carvykti(Cilta-cel) are approved for leukemia, lymphoma, and multiple myeloma
treatment [3-5]. These drugs use lentiviral or retroviral transfection to express anti-CD19/CD-38/B-cell maturation antigens on the CAR. Target cancer-specific antigen, and
upon activation, CAR-T cells are prompted to proliferate in-vivo and attack the cancer
cells. CD-19 is an attractive surface marker for B-cell malignancies, such as leukemia or
lymphoma, because it is expressed in all stages of B-cell differentiation [6, 7]. CAR-T
therapy has shown promising results and provides a new therapeutic option, especially for
patients with relapsed/refractory lymphoma; however, there are safety concerns and
manufacturing challenges.
CAR-T cell therapy has several side effects with varying intensities. Two of the
significant side effects are cytokine release syndrome (CRS) and neurotoxicity. CRS is
systemic inflammation in response to interleukins released by CAR-T cells. Patients are
monitored for signs of CRS such as fever, hypotension, and hypoxia, which can take
several days to develop. CAR-T-related neurologic toxicities can vary from mild cognitive
defects and tremors to seizures and death. CRS and neurologic toxicities can be managed
2

with steroids, but early detection and careful monitoring are essential to avoid lifethreatening complications [2]. Additionally, CAR-T therapy makes patients susceptible to
infections due to a severely suppressed immune system.
Several types of gene transfection methods are utilized for T-cell processing:
gamma retroviral and lentiviral transfection, electroporation, sonoporation, cationic lipidbased delivery, and squeeze technology. Viral transfection uses the nature of viruses in
which they hijack the host replication process allowing them to supplement the host genetic
code. Retroviral transfections utilize lentiviral or γretroviral vectors to deliver CAR
transgene into T-cells. Retroviral and lentiviral transfections methods are currently the
primary method for T-cell manipulation. Due to the nature of viral vectors, genes are
inserted randomly, which can lead to undesired mutagenesis and oncogenesis. Although
viral vectors are effective, there are mutagenesis safety concerns due to the variability in
viral gene transfection, which leads to surface expression that is uneven [8].
Non-viral transfection methods include physical and chemical techniques such as
electroporation, sonoporation, squeeze technology, and cationic lipid-based delivery. Nonviral transfection methods use a variety of nucleic acids for genetic manipulation, such as
small DNA, large DNA molecules (plasmid DNA), and RNA (Ribozymes, Si RNA, m
RNA) [9]. Electroporation is a transfection method that uses high voltage to create
temporary holes in the cell membrane allowing the substance of interest to enter the cell.
The delivery of the material is not dependent on the charge, and both small and large
molecules have been successfully delivered with this technique. Additionally, transfection
efficiency is lower for electroporation in comparison to viral transfection. The high voltage
required for this technique can damage the cells, and the effects of high electricity on the
3

genetic profile have not been fully characterized yet
[10]. This technique also requires special buffers

MB
Rupture

that conduct current efficiently [11]. Sonoporation is
a process that uses ultrasound waves to induce
microbubble cavitation which permeabilizes the cell
membrane (Figure 2). When microbubbles are
exposed to ultrasound, they oscillate in response to
the pressure difference. This rapid expansion and

Figure 2: Illustration of Sonoporation
Mechanism.

compression of the microbubbles will eventually result in microbubble rupture known as
inertial cavitation. Shock waves from inertial cavitation cause temporary pores in the cell
membrane that allows for intracellular delivery of nearby contents [12]. The pores formed
from inertial cavitation are momentary and repair within seconds once ultrasound is turned
off. This technique is a promising non-viral delivery method; however, widespread use of
this technique is limited due to the ultrasound setup needed. A microfluidic-based
technology known as cell squeeze utilizes high shear stress, exposing the cells to
mechanical deformation as they pass through very narrow channels. This high shear stress
creates temporary holes in the cell membrane that allows for nearby material to go inside
the cells. A few moments later, the cell membrane is restored. This mechanical deformation
technique has shown promising results in delivering a variety of cargo materials, such as
RNA, DNA, and CRISPR [13]. A challenge of this technology is the clogging of the narrow
channels due to cell aggregates or other materials. Clogged channels are a common
problem with microfluidic devices, especially when scaled up for processing [14]. Cationic
lipid-based delivery is a chemical mode of transfection, and it is referred to as lipofection
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or lipid-mediated/liposome transfection. In this technique, positively charged liposomes
interact with negatively charged DNA fragments and negatively charged cell membranes.
The material of interest is delivered to the cells via endocytosis, and excess unnecessary
materials are removed via exocytosis. This method has been proven effective for a wide
range of cells and various cargo materials such as DNA, RNA, and proteins of different
masses [10]. This technique has shown lower transfection efficiency in comparison to viral
methods.
Despite the potential efficacy of viral and non-viral transfection techniques, nonspecific random insertion of genes for CAR expression poses risks of accidental genetic
mutations or highly variable CAR expression between cells which can adversely affect
CAR-T treatment. Clustered regulatory interspaced short palindromic repeats (CRISPR)
and corresponding protein Cas9 provide gene-specific transfection for CAR-T processing.
CRISPR-Cas9 system uses a guide RNA to target the genome specifically, and Cas9 cuts
off the guide RNA once it matches with the DNA of the host. Unlike current viral and nonviral transfection techniques that use nucleic acids for gene editing that are inserted
randomly into the host genome, CRISPR/Cas9 allows for specific gene knockout/in [15].
CRISPR/Cas9 is expected to lower the side effects related to the current treatment with
CAR-T, such as Cytokine release syndrome (CRS) and neurotoxicity. The use of
CRISPR/Cas9 alongside viral transfection or other transfection methods such as the one
proposed here will lead to a safer and more potent CAR-T product [16]. The use of
CRISPR/Cas9 with CAR-T opens the possibility of allogeneic CAR-T cells, which can
provide an off-the-shelf product [15]. Current CAR-T products are autologous and require
the patient's T-Cells which can be challenging to acquire in cancer patients, lengthens the
5

manufacturing process, and a personalized product is more expensive than an off-the-shelf
product. Precision genome editing with CRISPR/Cas9 will help overcome current
obstacles because multiple genes can be targeted at once. The above-mentioned viral and
non-viral techniques have been used to transduce CRISPR/Cas9 using viral transfection
and electroporation [17]. While CRISPR/Cas9 systems address the problems such as CRS
and neurotoxicity, challenges with current viral and non-viral transfection techniques still
limit the use of CRISPR/Cas9 for CAR-T processing. Challenges with non-viral and viral
transfection prevent the large-scale production of CAR-T cells.
Problem
Current techniques used for transfection of genetic materials in the processing of
CAR-T cells present challenges that limit the use of this therapy. As mentioned above, both
viral and non-viral techniques have presented their limitations and challenges. Thus, there
is a need for a processing technique that delivers molecular compounds to T-cells
effectively and consistently and has the potential to be scaled up for higher throughput. The
3-D printed acoustofluidic system discussed here holds the potential to address these
limitations.
Bioengineering Solution: 3D Printed Acoustofluidic Device for Molecular Delivery
To address the limitations of current viral and non-viral gene-editing techniques,
Dr. Jonathan Kopechek’s laboratory at the University of Louisville is developing a 3Dprinted acoustofluidic device for molecular delivery. This system utilizes an ultrasonic
transducer with an acoustofluidic device to induce microbubble cavitation to permeabilize
the cell membrane for intracellular delivery of therapeutic compounds (Figure 3).
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Figure 3: Schematic
representation of how 3D
printed acoustofluidic device
mediated cell membrane rupture
will allow intra-cellular uptake
of surrounding molecular
components.

Ultrasound Transducer

Dr. Kopechek’s lab first tested the use of sonoporation for molecular delivery with a
clinical ultrasound probe. In this setup, the cell solution (cells, microbubbles, and
biomolecules) was in a conical vial which was placed in a water tank. The water served as
a medium for the ultrasonic waves to propagate. This technique was inefficient because the
cells received inconsistent ultrasound exposure due to the shielding of some cells by
microbubbles, and the ultrasound waves would attenuate before reaching the cells that were
on the backside of the conical vial [18]. The following iteration of this system was an
acoustofluidic device to provide consistent exposure to ultrasound. In this setup, the cell
solution (cells, microbubbles, and biomolecules) is pushed through the 3D printed device
with

a

peristaltic

pump.

A

clinical

ultrasound probe is placed directly above
the acoustofluidic device with a layer of
ultrasound gel which provides a medium for
ultrasonic waves (Figure 4). The cells pass
through a 1mm concentric spiral channel
directly under the ultrasound probe. A
concentric spiral design was chosen to
Figure 4: Set-up of 3D printed acoustofluidic device

optimize the cell exposure to ultrasound. with ultrasound imaging probe.

Experimental studies using this 3D-printed acoustofluidic device for intracellular
molecular delivery are discussed below.
7

II.

METHODS
Cell culture and Harvesting
Jurkat T lymphocytes were cultured in complete RPMI-1640 medium (10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin) (Cytiva Life Sciences, Marlborough,
MA, USA) at 37 °C and 5% CO2 in a flat-bottom tissue culture flask. A549 cells, MDAMB-231 cells, and HEK293 cells were cultured in complete DMEM medium with 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin) (Cytiva Life Sciences) at 37 °C
and 5% CO2 in a flat-bottom tissue culture flask. To harvest, A549 cells, MDA-MB-231
cells, and HEK293 cells were washed once with PBS, and trypsin was added to release
attached cells. After five minutes of incubation time, the cell/trypsin solution was
neutralized with complete DMEM medium and collected into a conical vial. These cells
were centrifuged at 1500g for 5 minutes at 4 °C. To harvest Jurkat T-lymphocytes, they
were collected in conical vials and centrifuged at 1500g for 5 minutes at 4 °C. Cells were
resuspended at a concentration of 100,000 cells/mL.
Microbubble Synthesis
Perfluorobutane gas-filled microbubbles were synthesized as previously described
[19]. These gas-filled microbubbles were created with a cationic lipid solution and had a
mean diameter of 2 ± 1 µm. Positively charged phospholipid-coated gas-filled
microbubbles were used for these studies as they were previously shown to be necessary
for effective acoustofluidic mediated molecular delivery[19-22]. Cationic microbubble
lipid solution comprised of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, Avanti
Lipids, Alabaster, AL, USA); 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSEPC,
Avanti Lipids); 1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG, Avanti Lipids); and
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polyethylene glycol-40 stearate (Sigma-Aldrich, St. Louis, MO, USA) at molar ratios of
100:43:1:4.5. Microbubbles with neutral surface charge were formulated with chloroform
solutions

of

DSPC

and

1,2

distearoyl-sn-glycerol-3-phosphoethanolamine-N-

[amino(polyethylene glycol0 -2000] (DSPC-PEG-2000, Avanti Lipids) at a molar ratio of
96:4[23]. These lipids were combined in a 20-mL glass vial and desiccated until all the
chloroform was removed. The dry lipid film was resuspended in 1x PBS and sonicated
(Qsonica, Newtown, CT, USA) to create an aqueous micellar lipid solution at a
concentration of 10mg/mL. The lipid solution was diluted in 4x PBS in a 2-mL glass vial
and sealed to produce microbubbles. The air in the headspace of the glass vial was replaced
with decafluorobutane gas (FlouroMed, Round Rock, TX, USA). The glass vial was then
amalgamated at 4350 cpm for 45 seconds (DB-338, COXO, Foshan City, China) to form
cationic microbubbles.
Trans-activating CRISPR RNA(tracrRNA) is one of three components of the
CRISPR/Cas9 system used for genome editing in cultured cells. To perform CRISPR/Cas9
genome editing, a CRISPR RNA(identifies the target DNA sequence) must bind to a
tracrRNA, activating the Cas9 endonuclease to create a functional editing
ribonucleoprotein complex. The tracrRNA used in our studies was fluorescently labeled
with ATTO550 to allow for analysis via flow cytometry. To form microbubbles with AltR CRISPR/Cas9 tracrRNA, ATTO 550(IDT Technologies, USA) the steps mentioned
above were followed. To produce tracrRNA-ATTO550 microbubbles the lipid solution and
tracrRNA-ATTO550 solution was diluted in PBS to a concentration of 5µg/mL in a 2-mL
glass vial and sealed. The air in the headspace of the glass vial was replaced with
decafluorobutane gas (FlouroMed, Round Rock, TX, USA). The glass vial was then
9

amalgamated at 4350 cpm for 45 seconds (DB-338, COXO, Foshan City, China) to form
cationic microbubbles. These steps were followed to create a tracrRNA-ATT50 diluted
solution without any gas or amalgamation steps.
Acoustofluidic Device Manufacturing
3D printed acoustofluidic device was designed in SolidWorks (Waltham, MA,
USA) and driven by a peristaltic pump. A 1mm x 1mm concentric spiral channel design
was chosen based on prior experiments for optimal molecular delivery (Figure 5) [20]. The
flow chamber was created using stereolithography 3D printing (Xometry, Gaithersburg,
MD,

USA)

on

Accura 60 plastic.
Inlet

and

outlet

openings of the flow
chamber

Figure 5: 3D printed acoustofluidic device with the concentric spiral channel

were design in the center of the device.

threaded with stainless steel barbed tube fittings (10-32 threads, McMaster-Carr, Elmhurst,
IL, USA) to link to PVC tubing (1/16” ID, McMaster-Carr). A peristaltic pump was used
to push the cell solution through the device at a flow rate of 1.5mL/min (Boxer GmbH,
Ottobeuren, Germany). An ATL P4-1 ultrasound transducer was placed directly above the
concentric spiral channel on the 3D-printed acoustofluidic device. A thin layer of
ultrasound gel was applied to the transducer and the acoustofluidic device to allow for
acoustic coupling. Verasonics Vantage 64LE ultrasound imaging system was used to
generate B-mode pulses at a frequency of 2.5MHz.

10

Molecular Delivery to Human Cells
A mixture of cationic microbubbles, the fluorescent molecule of interest (tracrRNA
ATTO-550), and Jurkat cells or HEK293 cells was pumped through the 3D printed
acoustofluidic system to expose the cells to ultrasound. Cationic microbubble and
tracrRNA-ATTO550 solution were added to the cell solution at a concentration of 5% v/v
before acoustofluidic treatment. After treatment, cells were collected and seeded in a 24well plate at 37 °C and 5% CO2 for 48 hours. After 48-hour incubation, cells were harvested
as described above and washed via centrifugation three times with PBS to remove any
remaining extracellular compounds.
FITC Dextran Delivery to Multiple Cell Lines
A mixture of cationic microbubbles, the fluorescent molecule of interest (150kDa
FITC-Dextran), and either Jurkat cells, A549 cells, MDA-MB-231 cells, or HEK293 cells,
was pumped through the 3D printed acoustofluidic system to expose the cells to ultrasound.
1.5mM 150kDa FITC-Dextran macromolecule was added to the cell and cationic
microbubble solutions directly before acoustofluidic treatment. Six concentrations of
cationic microbubbles were tested 0% v/v to 10.0% v/v. After acoustofluidic treatment,
cells were washed via centrifugation three times with PBS to remove extracellular FITCDextran and other debris. Propidium iodide (PI) stain was added to the cells to determine
cell viability before flow cytometry analysis.
GFP Delivery to Jurkat T-cells
A mixture of Jurkat cells, cationic microbubbles, and GFP (28kDa) was pumped
through the 3D printed acoustofluidic system to expose the cells to ultrasound. GFP (2 µM)
11

was directly added to the cell and cationic microbubble solutions before acoustofluidic
treatment. After acoustofluidic treatment, cells were washed via centrifugation three times
with PBS to remove extracellular GFP and other debris. Propidium iodide (PI) stain was
added to the cells before flow cytometry analysis to exclude non-viable cells.
Flow Cytometry Analysis
Intracellular molecular delivery was determined through the detection of
fluorescent compounds with a flow cytometer (MACSquant, Miltenyi Biotec, Bergisch
Gladbach, Germany). Flow cytometry channels were chosen based on appropriate
wavelengths for the fluorescent molecule of interest. Flow cytometry software, FlowJo
(FlowJo, Ashland, OR USA) was used to analyze flow cytometry data. Forward and side
scattering was used to gate live cells based on size and granularity. A histogram was
created to display the fluorescence intensity of the molecule of interest, the x-axis was the
logarithmic fluorescence intensity value, and the y-axis was the cell count. Mean
fluorescence intensity was calculated from the histogram. The average, standard deviation,
and fold change of these values were calculated in Microsoft Excel.
Statistical Analysis
Statistical analysis was performed using Minitab (State College, PA) and MS
Excel. A one-way variance (ANOVA) test was utilized to compare multiple groups. Posthoc analysis was used for comparison between groups with a Tukey’s test. A p-value less
than 0.05 was defined as statistically significant. Bars on the figures are representative of
means ± standard errors.
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III.

RESULTS AND DISCUSSION
Effect of Microbubble Concentration on Acoustofluidic Molecular Delivery in Different
Cell Lines
Acoustofluidic mediated molecular delivery of a fluorescent macromolecule
150kDa FITC-Dextran (1mM) was tested in four cell lines at six different cationic
microbubble concentrations. The following cell lines were tested: Jurkat T-cells Human
lymphocytes, MDA-MB-231 human breast carcinoma cells, human A549 lung carcinoma
cells, and HEK293 cells were tested at microbubble concentrations of 0%-10% v/v. The
cells were treated with acoustofluidic treatment and appropriate microbubble
concentration. Post-treatment, the cells were washed three times, and propidium iodide (PI)
stain was added before flow cytometry analysis. PI stain was used as an indicator of nonviable cells, and this measurement was used to calculate cell viability. Results of these
experimental trials are shown below in figures 5-8.

Figure 6: (A) Cationic microbubble concentration of 5% v/v significantly enhanced molecular delivery of
150kDa FITC-Dextran(1mM) to Jurkat T-cells. (B) Cell viability of Jurkat T-cells was significantly reduced
after acoustofluidic treatment for all microbubbles concentrations compared to the control group with no
microbubbles.
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Figure 6 shows the effects of different microbubble concentrations on
acoustofluidic mediated molecular delivery of 150kDa FITC-Dextran in Jurkat T-cells.
Intracellular delivery was significantly enhanced at a microbubble concentration of 5% v/v
when compared to concentrations of 0-1% v/v (ANOVA p<0.01, n=6/group) and 10% v/v
(p<0.05). Effects of microbubble concentration on cell viability, as indicated by the
absence of PI stain, are shown in Figure 5B. Acoustofluidic treatment significantly reduced
cell viability for all microbubble concentrations compared to the negative control group
with no microbubbles (ANOVA p<0.001, n=6/group). Furthermore, acoustofluidic
treatment at microbubble concentrations of 2.5% v/v – 7.5% v/v significantly reduced cell
viability in comparison to microbubble concentrations of 1% v/v and 10% v/v (p<0.001).

Figure 7: (C) Cationic microbubble concentration of 5% v/v significantly enhanced molecular delivery of
150kDa FITC-Dextran(1mM) to MDA-MB-231 cells. (D) Cell viability of MDA-MB-231 cells was
significantly reduced after acoustofluidic treatment for microbubble concentrations of 2.5%-7.5% v/v
compared to the control group with no microbubbles.

Figure 7 shows the effects of different microbubble concentrations on
acoustofluidic mediated molecular delivery of 150kDa FITC-Dextran (1mM) in MDAMB-231 cells and the corresponding effects on cell viability. Intracellular molecular
delivery of 150kDa FITC-Dextran was significantly enhanced at a microbubble
concentration of 5% v/v in comparison to microbubble concentrations of 0%-2.5% v/v and
14

7.5% v/v (ANOVA p<0.001, n=6/group). Effects of microbubble concentration on cell
viability, as indicated by the absence of PI stain, are shown in Figure 6D. Acoustofluidic
treatment at microbubble concentrations of 2.5%-7.5% v/v reduced cell viability
significantly compared to the negative control group with no microbubbles (p<0.001).

Figure 8: (E) Cationic microbubble concentration of 5% v/v significantly enhanced molecular delivery of
150kDa FITC-Dextran(1mM) to A549 cells. (F) Cell viability of A549 cells was significantly reduced after
acoustofluidic treatment at a microbubble concentration of 5% v/v compared to microbubble concentrations
of 0%-2.5% v/v and 7.5%-10% v/v.

Figure 8 shows the effects of different microbubble concentrations on
acoustofluidic mediated molecular delivery of 150kDa FITC-Dextran (1mM) in A549
human lung carcinoma cells and the corresponding effects on cell viability. Intracellular
molecular delivery of 150kDa FITC-Dextran was significantly enhanced at a microbubble
concentration of 5% v/v compared to the negative control group with no microbubbles
(ANOVA p<0.001, n=9/group). Effects of microbubble concentration on cell viability, as
indicated by the absence of PI stain, are shown in Figure 7F. Acoustofluidic treatment at a
microbubble concentration of 5% v/v reduced cell viability significantly compared to
microbubble concentrations at 2.5%-7.5% v/v (p<0.001).
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Figure 9: (G) Cationic microbubble concentration of 5% v/v significantly enhanced molecular delivery of
150kDa FITC-Dextran(1mM) to HEK293 cells. (H) Cell viability of HEk293 cells was significantly reduced
after acoustofluidic treatment at microbubble concentrations of 2.5%-10%v/v compared to the control group
with no microbubbles.

Figure 9 shows the effects of different microbubble concentrations on
acoustofluidic mediated molecular delivery of 150kDa FITC-Dextran (1mM) in HEK293
cells and the corresponding effects on cell viability. Intracellular molecular delivery of
150kDa FITC-Dextran was significantly enhanced at all microbubble concentrations of 110% v/v compared to the negative control group with no microbubbles (ANOVA p<0.01,
n=3-6/group). Effects of microbubble concentration on cell viability, as indicated by the
absence of PI stain, are shown in Figure 8H. Acoustofluidic treatment at microbubble
concentrations of 5%-10% v/v reduced cell viability significantly (ANOVA p<0.01, n=36/groups) and 2.5% v/v (p<0.05) when compared to the negative control group with no
microbubbles. Additionally, cell viability remained above 80% for all groups.
TracrRNA Delivery to HEK293 Cells
Acoustofluidic mediated molecular delivery of a fluorescently labeled tracrRNA
(ATTO-550) was tested in two different cell lines at varying conditions. A fluorescently
labeled tracrRNA was used because successful intracellular delivery can be detected via
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flow cytometry. tracrRNA is a ribonucleoprotein (RNP) that is an essential part of the
CRISPR/Cas9 system. The cells were treated with acoustofluidic treatment at appropriate
conditions, and all samples were washed after incubation and before flow cytometry was
used to assess intracellular delivery. Results of these experiments in HEK293 cells and
human lymphocytes Jurkat T-cells are shown below.

Figure 10: Cationic microbubbles (in both the flow only and the acoustofluidic treatment groups)
significantly enhance tracrRNA uptake in HEK293 cells from 0 h- 48h with or without acoustofluidic
treatment, compared to tracrRNA alone without microbubbles (n=3/group).

Figure 10 shows acoustofluidic mediated molecular delivery of tracrRNA in
HEK293 cells over three different time points of zero hours, 24 hours, and 48 hours. All
three-time points were statistically significant, as indicated by an ANOVA test and
ANOVA p-value of ≤ 0.001 (n=3/group). Post-hoc analysis indicated that acoustofluidic
treatment and flow only (no ultrasound) groups had significantly higher relative
fluorescence when compared to cells only and no-treatment groups.
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Figure 11: Cationic microbubbles (in both the flow only and the acoustofluidic treatment groups)
significantly enhance tracrRNA uptake in HEK293 cells compared to neutral microbubbles, with or without
acoustofluidic treatment (n=3/group).

Figure 11 shows acoustofluidic mediated molecular delivery of tracrRNA in
HEK293 cells with cationic microbubbles and neutral microbubbles over an incubation
period of 48 hours. These results are statistically significant, as indicated by an ANOVA
p-value of ≤ 0.001 (n=3/group). Post-hoc analysis results found that cationic microbubbles
with flow only (no ultrasound) and cationic microbubbles with acoustofluidic treatment
had significantly higher relative fluorescence intensity when compared to the rest of the
groups (including neutral microbubble flow only and acoustofluidic treatment groups).
These results indicate that cationic microbubbles enhance intracellular uptake of tracrRNA
in comparison to neutral microbubbles.
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Figure 12: Washing HEK293 cells immediately after acoustofluidic treatment limits intracellular uptake of
tracrRNA (n=6/group).

Figure 12 shows the effects of washing HEK293 cells directly after acoustofluidic
treatment on molecular delivery of tracrRNA. The cells were treated with acoustofluidic
treatment and washed three times with PBS following treatment to remove any
extracellular compounds. ANOVA testing revealed these results not to be statistically
significant as the p-value was not ≤ 0.05. These results indicate that washing cells
immediately after acoustofluidic treatment prevents intracellular uptake of tracrRNA.

19

TracrRNA Delivery to Jurkat T-Cells

Figure 13: Cationic microbubbles significantly enhance tracrRNA uptake in Jurkat T-cells from 0 h- 48h with
or without acoustofluidic treatment, compared to tracrRNA alone without microbubbles (n=2-3/group).

Figure 13 shows acoustofluidic mediated molecular delivery of tracrRNA in Jurkat
T-cells over three different time points of zero hours, 24 hours, and 48 hours. All three
times were statistically significant, as indicated by an ANOVA test and ANOVA p-value
of ≤ 0.001(n=2-3/group). Post-hoc test results revealed that acoustofluidic treatment and
flow only (no ultrasound) groups had significantly higher relative fluorescence intensity
than cells only and no treatment (tracrRNA only) groups. These results indicate that flow
only and acoustofluidic treatment both significantly enhance intracellular delivery of
tracrRNA in Jurkat T-cells at all three-time points.
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Figure 14: Cationic microbubbles significantly enhance tracrRNA uptake in Jurkat T-cells compared to
neutral microbubbles, with or without acoustofluidic treatment (n=3-15/group).

Figure 14 shows acoustofluidic mediated molecular delivery of tracrRNA in Jurkat
T-cells with cationic microbubbles and neutral microbubbles over an incubation period of
48 hours. These results are statistically significant, as indicated by an ANOVA p-value of
≤ 0.001(n=3-15/group). Post-hoc test results found that acoustofluidic treatment with
cationic microbubbles had significantly higher relative fluorescence intensity when
compared to the other groups. These results indicate that cationic microbubbles with
acoustofluidic treatment enhance intracellular uptake of tracrRNA in comparison to neutral
microbubbles and acoustofluidic treatment.
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Figure 15: Washing Jurkat-T cells immediately after acoustofluidic treatment limits intracellular uptake of
tracrRNA (n=5-6/group).

Figure 15 shows the effects of washing Jurkat T-cells directly after acoustofluidic
treatment on molecular delivery of tracrRNA. The cells were treated with acoustofluidic
treatment and washed three times with PBS following treatment to remove any
extracellular compounds. ANOVA testing revealed these results not to be statistically
significant as the p-value was not ≤ 0.05 (n=5-6/group). These results indicate that washing
cells immediately after acoustofluidic treatment prevents intracellular uptake of tracrRNA.
Acoustofluidic mediated GFP Delivery to Jurkat T-Cells
Acoustofluidic mediated molecular delivery of green fluorescent protein (GFP) was
tested in Jurkat T-cells. The cells were treated with acoustofluidic treatment as described
in the methods section. Post-treatment, the cells were washed three times, and propidium
iodide (PI) stain was added before flow cytometry analysis. PI stain was used as an
indicator of non-viable cells, and this was used to calculate cell viability.
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Figure 16: Acoustofluidic treatment significantly enhanced molecular delivery of GFP in Jurkat T-cells in
comparison to no treatment group (n=3-6/group). Additionally, cell viability remained relatively high with
acoustofluidic treatment.

Figure 16 shows the acoustofluidic mediated intracellular delivery of GFP in Jurkat
T-cells. Acoustofluidic treatment significantly enhanced molecular delivery of GFP in
comparison to the no treatment group (p<0.001, n=3-6/group). The flow-only group did
not show a significant increase in fluorescence compared to the no-treatment group
(p=0.06, n=3-6/group). Additionally, cell viability was not negatively impacted by
acoustofluidic treatment as cell viability remained greater than 80% for all groups.
Discussion
The 3D-printed acoustofluidic system enhanced molecular delivery in various cell
lines, as demonstrated by the studies conducted in this thesis. These results show promise
that this 3D-printed acoustofluidic system may enable improved techniques for the nonviral processing of cells for gene therapy applications. The effects of varying microbubble
concentrations on the efficiency of acoustofluidic mediated molecular delivery of
macromolecule 150kDa FITC-Dextran and cell viability of four different cell lines were
assessed to determine optimal microbubble concentrations. These four cell lines were used
to test molecular delivery to determine differences between cell types. These cell lines had
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different properties and characteristics that may affect molecular delivery, such as the cell
size, shape, and whether these cells are in suspension or adherent during culture.
Additionally, HEK293 cells are often recommended for transfection and are known to have
a high transfection efficiency [24]. These preliminary studies were conducted with Jurkat
T-cells to optimize molecular delivery before testing with primary T-cells. There was some
variance in the results between cell lines, still, all cell lines showed significantly enhanced
molecular delivery at microbubble concentrations of 5% v/v in comparison to the negative
control group without microbubbles and ultrasound treatment. Furthermore, the cell
viability decreased for all cell lines at a microbubble concentration of 5% v/v compared to
the negative control group without microbubbles and without ultrasound treatment.
However, cell viability remained relatively high for groups and cell types. Increased
microbubble concentration, greater than 5% v/v, reduced intracellular delivery of 150kDa
FITC-Dextran while maintaining relatively high cell viability. An increased microbubble
concentration is generally linked to reduced cell viability due to cytotoxic effects [25]. A
possible explanation of this trend is “shadowing” because of decreased microbubble
oscillation due to increased scattering of ultrasound waves at higher concentrations of
microbubbles (10% v/v). Previous studies have described similar trends with different cell
lines and microfluidic devices [20, 26]. These results indicate an ideal “therapeutic
window” of microbubble concentrations that enhance acoustofluidic mediated intracellular
delivery of molecules. These results demonstrate that acoustofluidic treatment with
cationic microbubbles is effective at intracellular molecular delivery of macromolecules
such as 150kDa FITC-Dextran in multiple cell lines without dramatically compromising
cell viability. 150kDa FITC-Dextran was chosen as the test molecule because it is a
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fluorescent macromolecule that can be detected via flow cytometry. Additionally, 150kDa
FITC-Dextran is similar in size to CRISPR/Cas9 protein which is 160kDa. These
experiments suggest that the 3D-printed acoustofluidic system described above may be
effective at intracellular delivery of the CRISPR/Cas9 system for gene editing for CAR-T
therapy. Further studies are required to assess the ability of functional gene editing with
the CRISPR/Cas9 system using the 3D printed acoustofluidic device.
The effects of incubation time, microbubble charge, and immediate washing of cells
after acoustofluidic treatment on the intracellular delivery of tracrRNA in HEK293 cells
and human lymphocytes Jurkat T-cells are shown above. A fluorescently labeled tracrRNA
was used for these studies because tracrRNA is a crucial component of the CRISPR/Cas9
system, which was discussed as a possible solution to reduce the current side effects of
CAR-T therapy. Additionally, flow cytometry can be utilized to detect intracellular
delivery since the tracrRNA had a fluorophore attached to it. These studies looked at the
effects of incubation periods to determine if more extended incubation periods enhanced
intracellular delivery. A 48-hour incubation period was chosen because it is the
recommended time for current transfection techniques. Two more time points were tested
to determine how critical time point is and whether molecular delivery was affected by a
prolonged incubation period. There was variance in results between the two cell types at
different time points. However, both cell types had significantly higher intracellular
delivery of tracrRNA at 48 hours than tracrRNA only, as indicated by ANOVA p-value
<0.001 and posthoc analysis. These results suggest that the tracrRNA remained inside the
cell 48 hours post-treatment/incubation and washing steps. However, it is possible that the
tracrRNA may have degraded after 48 hours as these experiments did not test for intact
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tracrRNA. Future studies should test for tracrRNA using PCR testing to determine if the
tracrRNA remained intact for 48 hours or if only the fluorophore was inside the cell after
48 hours. In these experiments, acoustofluidic treatment significantly enhanced molecular
delivery while maintaining cell viability above 80%. These experiments suggest that RNP,
an essential part of the CRISPR/Cas9 system, can be intracellularly delivered to both
HEK293 cells and Jurkat T-cells using the 3D printed acoustofluidic system. Similar results
were shown in the studies with GFP protein (28kDa) molecular delivery. GFP was chosen
as a test molecule because it is a protein that is different in characteristics compared to the
other molecules tested. GFP is also a fluorescent molecule that allows for easy analysis
through flow cytometry. Successful delivery of a protein with the acoustofluidic system
described above is a promising result and affirms the potential use of this non-viral
technique for gene editing.
Experimental results of cationic versus neutral microbubble for intracellular
delivery of tracrRNA in both HEK293 and Jurkat T-cells were similar. In both cell lines,
cationic microbubbles significantly increased intracellular delivery of tracrRNA. However,
in HEK293 cells, the cationic microbubbles enhanced intracellular delivery with or without
acoustofluidic treatment, and in Jurkat T-cells, only the acoustofluidic treated group had
significantly higher intracellular delivery. These results demonstrate that cationic
microbubbles alone without ultrasound treatment may be sufficient to induce intracellular
delivery of tracrRNA in HEK293 cells. This can be explained due to the cationic/anionic
interaction between the microbubbles and cell surface/tracrRNA. Some intracellular uptake
of tracrRNA may be induced because of this interaction and prolonged incubation time
which is sufficient for endocytosis. However, washing the cells immediately after
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acoustofluidic treatment significantly reduced intracellular delivery of tracrRNA in both
HEK293 cells and Jurkat T-cells. Washing cells immediately after acoustofluidic treatment
and before incubation reduced fluorescent intensity across all groups for both cell lines. A
possible explanation for this could be the immediate removal of cationic microbubbles that
may be attached to the cell surface, which may promote uptake over time with cellular
mechanisms. These results indicate that it may cationic microbubbles, and flow treatment
without ultrasound may induce molecular uptake alone.
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IV.

CONCLUSIONS
This thesis provides new findings regarding acoustofluidic meditated molecular
delivery in multiple cell lines. A 3D-printed acoustofluidic device was utilized for
intracellular molecular delivery of macromolecule 150kDa FITC-Dextran in four different
cell types: Jurkat T-cells, MDA-MB-231 cells, A549 cells, and HEK 293 cells. Results of
these studies indicated that there is an optimal range of cationic microbubble concentration
for enhanced intracellular delivery without compromising viability of most cells.
Microbubble concentration of 5% v/v proved to be most efficient for all cell types
compared to lower and higher concentrations. Additionally, these studies demonstrated that
acoustofluidic mediated molecular delivery of macromolecules is possible with the 3D
printed system in multiple cell lines. Since 150kDa FITC-Dextran and CRISPR/Cas9
protein is similar in size, the 3D printed acoustofluidic system holds promise for a novel
non-viral transfection method for CAR-T cell processing.
Additional studies were conducted to test the efficiency of the 3D printed
acoustofluidic device for intracellular molecular delivery of a fluorescently labeled
tracrRNA in HEK293 cells and Jurkat T-cells. Several parameters were assessed in these
studies: the effects of time points on molecular delivery, the effects of cationic
microbubbles compared to neutral microbubbles on molecular delivery, and the effects of
washing cells post acoustofluidic treatment on molecular delivery. Intracellular delivery of
tracrRNA was significantly enhanced with cationic microbubbles with or without
acoustofluidic treatment in both cell lines at all three-time points (0hr, 24hr, 48hr). These
results indicate that our 3D printed acoustofluidic device with cationic microbubbles can
provide rapid intracellular take up of molecules such as tracrRNA. Cationic microbubbles
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with acoustofluidic treatment proved to be more effective at intracellular molecular
delivery of tracrRNA in both cell lines in comparison to neutral microbubbles with
acoustofluidic treatment. Studies also revealed that washing cells post acoustofluidic
treatment prevented intracellular uptake of tracrRNA in both cell lines. These results
indicate that cationic microbubbles are essential for optimal intracellular uptake of genetic
materials such as tracrRNA, essential for gene editing. Thus, combining cationic
microbubbles with the 3D printed acoustofluidic system described in this thesis holds the
potential to be used as a non-viral transfection method for the CRISPR/Cas9 system since
effective delivery of both tracrRNA and a macromolecule that is comparable to cas9 were
demonstrated in this study.
Future Recommendations
Future studies should focus on assessing the functional delivery of biological
molecules such as proteins, DNA, and RNA into Jurkat T-cells using the 3D-printed
acoustofluidic device. Insights garnered in this study, such as optimal microbubble
concentrations and effects of washing cells post-treatment, should be utilized to format
future studies. Additionally, studies should consider the effect of cationic microbubbles on
inducing molecular uptake with more experiments. Microbubble characteristics such as
size, shape, and formulations should be explored more to understand some of the results of
this thesis more thoroughly. Furthermore, studies should be conducted to determine the
ideal tracrRNA to microbubble lipid concertation. There will likely be a threshold of
tracrRNA concentration before microbubble size and shape are deformed. In addition, the
surface area (~ 3-28 µm2 for microbubble diameter of ~ 1-3 µm) of the microbubbles limits
how much tracrRNA can be attached to the microbubble before it is completely saturated.
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Thus, finding the optimal tracrRNA to microbubble ratio is important to optimize
molecular delivery.
Additional studies should focus on showing the functional delivery of proteins,
DNA, and RNA. A gene cleavage assay can serve as an indicator of functional gene editing.
Two components are needed to perform functional genome editing with CRISPR-Cas9: a
guide RNA (gRNA) and Cas9 (cleavage protein). Guide RNA(gRNA) consists of CRISPR
RNA(crRNA), which indicates the specific DNA target sequence, and a transactivating
crRNA(tracrRNA) which binds to the crRNA and Cas9 protein to form a ribonucleoprotein
complex. gRNA along with Cas9 protein should be intracellularly delivered to Jurkat Tcells using the 3D printed acoustofluidic system with cationic microbubbles. After 48 hours
of incubation, cells should be harvested and prepared for DNA isolation. Standard protocol
or DNA isolation kits should be utilized to break open the cells and extract only the DNA.
Then, the DNA needs to be expanded using polymerase chain reaction (PCR), which allows
for the copying of specific regions of the DNA with sequence-specific primers. The
crRNA-specific target sequence should be chosen for PCR. Finally, gel electrophoresis is
to be performed to isolate the nucleic acids based on size and charge. The gel is stained
with a dye that allows for nucleic acid fragments to be visible as bands. If the target-specific
fragment bands are visible, then genome editing was successful. Since the current studies
only prove intracellular delivery of biological molecules and not functional gene editing.
As mentioned above, with the current studies, it is not possible to determine whether the
tracrRNA had degraded at 48 hours and only the fluorophore was inside the cell. Flow
cytometry was utilized to detect intracellular fluorescence; however, moving forward,
advanced techniques such as confocal microscopy should be used to determine the location
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of the tracrRNA. Another limitation of the current study is the lack of studies on the effects
of temperature, cell cycle phase, and cell culture techniques on acoustofluidic mediated
molecular delivery. Higher temperatures could increase both diffusion and metabolic rate,
which may increase endocytic uptake [25, 27]. Thus, studies should be performed at
various temperatures to assess how it influences acoustofluidic mediated molecular
delivery. Another limitation of the current studies is the lack of focus on ultrasound
parameters. Ultrasound parameters such as frequency, pressure, and time under ultrasound
treatment may impact intracellular delivery. In addition, studies should be conducted to
assess how cationic microbubbles alone without ultrasound may be inducing intracellular
delivery. Further studies are required to understand this phenomenon and its ramifications
on the 3D-printed acoustofluidic system. If cationic microbubbles prove to be effective at
efficiently delivering molecules to cells, then design changes may be required to the current
system. Lastly, these studies should be used to create a protocol for acoustofluidic mediated
molecular delivery in primary T-cells. Studies with primary T-cells should be conducted
once an optimized protocol is developed for acoustofluidic mediated molecular delivery of
gene editing compounds. Suppose these studies show successful genome editing with the
3D printed acoustofluidic system with cationic microbubbles. In that case, this system may
address the current limitations of viral and non-viral transfection techniques, which limits
the use of CAR-T and other immunotherapies. Additional testing and development may
allow for the 3D-printed acoustofluidic system to be used for gene editing for
immunotherapies such as CAR-T to treat cancer and other diseases.
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